ArticleDrug design, development and therapy2025
Analysis of the Network Pharmacology Mechanism and Clinical Efficacy of Qingre Jiedu Decoction (QJD) in the Treatment of Infectious Mononucleosis (IM) in Children.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver diseaseWorld journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to clarify the molecular mechanisms of Qingre Jiedu Decoction (QJD), a traditional Chinese medicine (TCM), in treating infectious mononucleosis (IM). By combining network pharmacology and clinical trial validation, the research sought to understand how QJD interacts with biological pathways to combat IM. Methods: The research team identified active compounds and their targets in QJD using databases like TCMSP and STITCH. Genes related to IM were sourced from NCBI and DisGeNET. These data were used to construct a protein-protein interaction (PPI) network with STRING, visualizing interactions between QJD targets and IM-related genes. Functional enrichment analyses were conducted, including GO biological process analysis via Cytoscape ClueGo and KEGG pathway analysis using R's Clusterprofile package. A clinical trial involving 97 pediatric IM patients (53 in the experimental group, 44 in the control group) evaluated QJD's real-world efficacy. Results: The study identified 156 active compounds and 401 targets in QJD, along with 15 potential therapeutic targets for IM. In the clinical trial, the experimental group showed a significantly higher negative rate of plasma EBV (Epstein-Barr virus)-DNA post-treatment, indicating a stronger antiviral effect. Peripheral blood lymphocyte counts, CD3 Conclusion: QJD's multi-component effects contribute to its antiviral activity against EBV by modulating cytokine-mediated signaling pathways. This finding provides a scientific basis for QJD's clinical use in IM and underscores the potential of integrating network pharmacology with clinical trials to elucidate TCM mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.